The Sphingosine 1-Phosphate Signaling Pathway in Epilepsy: A Possible Role for the Immunomodulator Drug Fingolimod in Epilepsy Treatment.

No abstract is available for this paper.

• Publication year

  2017

• Venue

  CNS and Neurological Disorders - Drug Targets

• Publication date

  2017-03-31

• Fields of study

  Medicine

• Identifiers
  DOI 10.2174/1871527315666161104163031PMID 27823573
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fingolimod enhances myelin repair of hippocampus in pentylenetetrazol‐induced kindling model

  2017cited by this paper
• Clinical Trials of Immunomodulation in Ischemic Stroke

  2016cited by this paper
• Fingolimod for multiple sclerosis and emerging indications: appropriate patient selection, safety precautions, and special considerations

  2016cited by this paper
• Everolimus improves memory and learning while worsening depressive- and anxiety-like behavior in an animal model of depression.

  2016cited by this paper
• Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with meta-analysis of risk factors.

  2016cited by this paper
• Epilepsy in cerebrovascular diseases: Review of experimental and clinical data with meta‐analysis of risk factors

  2016cited by this paper
• Cannabidiol and epilepsy: Rationale and therapeutic potential.

  2016cited by this paper
• From Cannabis to Cannabidiol to Treat Epilepsy, Where Are We?

  2016cited by this paper
• Neuronal migration disorders: Focus on the cytoskeleton and epilepsy.

  2016cited by this paper
• FTY720/Fingolimod Reduces Synucleinopathy and Improves Gut Motility in A53T Mice

  2016cited by this paper
• Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial.

  2016cited by this paper
• mTOR Signaling in Epilepsy and Epileptogenesis: Preclinical and Clinical Studies

  2016cited by this paper
• Intractable epilepsy and the P-glycoprotein hypothesis

  2016cited by this paper
• mTOR pathway inhibition as a new therapeutic strategy in epilepsy and epileptogenesis.

  2016cited by this paper
• Upholding WAG/Rij rats as a model of absence epileptogenesis: Hidden mechanisms and a new theory on seizure development.

  2016cited by this paper
• Fingolimod: A Disease-Modifier Drug in a Mouse Model of Amyotrophic Lateral Sclerosis

  2016cited by this paper
• Sphingosine 1-phosphate signaling at the blood-brain barrier.

  2015influential reference
• The Direct Effects of Fingolimod in the Central Nervous System: Implications for Relapsing Multiple Sclerosis

  2015cited by this paper
• Sphingosine 1-phosphate enhances the excitability of rat sensory neurons through activation of sphingosine 1-phosphate receptors 1 and/or 3

  2015cited by this paper
• Fingolimod (FTY720) enhances hippocampal synaptic plasticity and memory in Huntington's disease by preventing p75NTR up-regulation and astrocyte-mediated inflammation.

  2015cited by this paper
• Antidepressant activity of fingolimod in mice

  2015cited by this paper
• Antidepressants but not antipsychotics have antiepileptogenic effects with limited effects on comorbid depressive‐like behaviour in the WAG/Rij rat model of absence epilepsy

  2015cited by this paper
• Sphingosine 1‐phosphate is a ligand for peroxisome proliferator‐activated receptor‐γ that regulates neoangiogenesis

  2015cited by this paper
• Are big potassium-type Ca2+-activated potassium channels a viable target for the treatment of epilepsy?

  2015cited by this paper
• Imaging microstructural damage and plasticity in the hippocampus during epileptogenesis.

  2015cited by this paper
• Valproic acid induces neuronal cell death through a novel calpain‐dependent necroptosis pathway

  2015cited by this paper
• Status epilepticus, blood-brain barrier disruption, inflammation, and epileptogenesis.

  2015cited by this paper
• A Case of Posterior Reversible Encephalopathy Syndrome Associated with Gilenya® (Fingolimod) Treatment for Multiple Sclerosis

  2015cited by this paper
• Fingolimod for the treatment of neurological diseases—state of play and future perspectives

  2014influential reference
• The Potential of Antiseizure Drugs and Agents that Act on Novel Molecular Targets as Antiepileptogenic Treatments

  2014cited by this paper
• Active, phosphorylated fingolimod inhibits histone deacetylases and facilitates fear extinction memory

  2014cited by this paper
• Epilepsy and Inflammation in the Brain: Overview and Pathophysiology

  2014cited by this paper
• FTY720 (fingolimod) is a neuroprotective and disease-modifying agent in cellular and mouse models of Huntington disease.

  2014cited by this paper
• Does mossy fiber sprouting give rise to the epileptic state?

  2014cited by this paper
• Reconceptualizing adult neurogenesis: role for sphingosine-1-phosphate and fibroblast growth factor-1 in co-ordinating astrocyte-neuronal precursor interactions.

  2014cited by this paper
• Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial.

  2014cited by this paper
• Role of GFAP in CNS injuries.

  2014cited by this paper
• Central effects of fingolimod.

  2014cited by this paper
• Nonpsychotropic plant cannabinoids, cannabidivarin (CBDV) and cannabidiol (CBD), activate and desensitize transient receptor potential vanilloid 1 (TRPV1) channels in vitro: potential for the treatment of neuronal hyperexcitability.

  2014cited by this paper
• Searching for the Ideal Antiepileptogenic Agent in Experimental Models: Single Treatment Versus Combinatorial Treatment Strategies

  2014cited by this paper
• Past and Present Definitions of Epileptogenesis and Its Biomarkers

  2014cited by this paper
• Antagonism of sphingosine 1-phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct-ligated rodents

  2014cited by this paper
• Comparative Analysis of the Treatment of Chronic Antipsychotic Drugs on Epileptic Susceptibility in Genetically Epilepsy-prone Rats

  2014cited by this paper
• Effects of brain IKKβ gene silencing by small interfering RNA on P-glycoprotein expression and brain damage in the rat kainic acid-induced seizure model.

  2014cited by this paper
• Loss of the neuroprotective factor Sphingosine 1-phosphate early in Alzheimer’s disease pathogenesis

  2014cited by this paper
• Sphingosine-1-phosphate and its receptors: structure, signaling, and influence.

  2013cited by this paper
• Antiepileptic action of N-palmitoylethanolamine through CB1 and PPAR-α receptor activation in a genetic model of absence epilepsy.

  2013cited by this paper
• FTY720 inhibits tumor growth and enhances the tumor‐suppressive effect of topotecan in neuroblastoma by interfering with the sphingolipid signaling pathway

  2013cited by this paper
• Issues related to symptomatic and disease‐modifying treatments affecting cognitive and neuropsychiatric comorbidities of epilepsy

  2013cited by this paper
• Sphingosine lysolipids in the CNS: endogenous cannabinoid antagonists or a parallel pain modulatory system?

  2013cited by this paper
• Dual effects of daily FTY720 on human astrocytes in vitro: relevance for neuroinflammation

  2013cited by this paper
• Fingolimod phosphate promotes the neuroprotective effects of microglia.

  2013cited by this paper
• Issues related to development of antiepileptogenic therapies

  2013cited by this paper
• Fingolimod Phosphate Attenuates Oligomeric Amyloid β–Induced Neurotoxicity via Increased Brain-Derived Neurotrophic Factor Expression in Neurons

  2013cited by this paper
• The structure and function of the S1P1 receptor.

  2013cited by this paper
• Critical role of sphingosine-1-phosphate receptor 2 (S1PR2) in acute vascular inflammation.

  2013cited by this paper
• The astrocyte in multiple sclerosis revisited

  2013cited by this paper
• FTY720 (Fingolimod) Attenuates Beta-amyloid Peptide (Aβ42)-Induced Impairment of Spatial Learning and Memory in Rats

  2013cited by this paper
• CB1 agonists, locally applied to the cortico-thalamic circuit of rats with genetic absence epilepsy, reduce epileptic manifestations.

  2013cited by this paper
• Development of new treatment approaches for epilepsy: Unmet needs and opportunities

  2013cited by this paper
• Antagonism of sphingosine 1‐phosphate receptor 2 causes a selective reduction of portal vein pressure in bile duct‐ligated rodents

  2012cited by this paper
• Fingolimod (FTY720) inhibits neuroinflammation and attenuates spontaneous convulsions in lithium-pilocarpine induced status epilepticus in rat model.

  2012influential reference
• Sphingosine 1-Phosphate Receptor 1 as a Useful Target for Treatment of Multiple Sclerosis

  2012cited by this paper
• Induction of brain tumor stem cell apoptosis by FTY720: a potential therapeutic agent for glioblastoma.

  2012cited by this paper
• Localized Sphingolipid Signaling at Presynaptic Terminals Is Regulated by Calcium Influx and Promotes Recruitment of Priming Factors

  2012cited by this paper
• Regulation of Autophagy and Its Associated Cell Death by “Sphingolipid Rheostat”

  2012cited by this paper
• Blood–brain barrier dysfunction and epilepsy: Pathophysiologic role and therapeutic approaches

  2012cited by this paper
• Inflammatory events at blood–brain barrier in neuroinflammatory and neurodegenerative disorders: Implications for clinical disease

  2012cited by this paper
• Targeting blood-brain barrier sphingolipid signaling reduces basal P-glycoprotein activity and improves drug delivery to the brain

  2012cited by this paper
• Sphingosine-1-phosphate signaling and its role in disease.

  2012influential reference
• Clinical Pharmacokinetics of Fingolimod

  2012influential reference
• The mTOR Signaling Pathway in the Brain: Focus on Epilepsy and Epileptogenesis

  2012cited by this paper
• A TrkB Small Molecule Partial Agonist Rescues TrkB Phosphorylation Deficits and Improves Respiratory Function in a Mouse Model of Rett Syndrome

  2012cited by this paper
• The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators

  2011cited by this paper
• Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis

  2011influential reference
• Endogenous sphingosine 1-phosphate regulates spontaneous glutamate release from mossy fiber terminals via S1P(3) receptors.

  2011cited by this paper
• Frequent spontaneous seizures followed by spatial working memory/anxiety deficits in mice lacking sphingosine 1-phosphate receptor 2.

  2011cited by this paper
• FTY720 Analogues as Sphingosine Kinase 1 Inhibitors

  2011influential reference
• Fingolimod provides long‐term protection in rodent models of cerebral ischemia

  2011influential reference
• Gilenya (FTY720) inhibits acid sphingomyelinase by a mechanism similar to tricyclic antidepressants.

  2011cited by this paper
• S1P Is Associated with Protection in Human and Experimental Cerebral Malaria

  2011cited by this paper
• Sphingosine-1-Phosphate Receptor-2 Function in Myeloid Cells Regulates Vascular Inflammation and Atherosclerosis

  2011cited by this paper
• Neurobiology of depression as a comorbidity of epilepsy

  2010cited by this paper
• Sphingosine 1‐phosphate receptor 1 and 3 are upregulated in multiple sclerosis lesions

  2010cited by this paper
• Altered expression of sphingosine kinase 1 and sphingosine-1-phosphate receptor 1 in mouse hippocampus after kainic acid treatment.

  2010cited by this paper
• FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation

  2010cited by this paper
• Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis.

  2010cited by this paper
• Tumor and Stem Cell Biology Cancer Research S 1 P 2 , the G Protein – Coupled Receptor for Sphingosine-1-Phosphate , Negatively Regulates Tumor Angiogenesis and Tumor Growth In vivo in Mice

  2010cited by this paper
• Sphingosine kinase/sphingosine 1-phosphate signalling in central nervous system.

  2009cited by this paper
• Sphingosine 1-phosphate receptor signaling.

  2009cited by this paper
• Sphingosine‐1‐phosphate receptors mediate neuromodulatory functions in the CNS

  2009cited by this paper
• Ceramide Synthesis Is Modulated by the Sphingosine Analog FTY720 via a Mixture of Uncompetitive and Noncompetitive Inhibition in an Acyl-CoA Chain Length-de pend ent Manner*

  2009cited by this paper
• Sphingosine-1-phosphate induced mTOR-activation is mediated by the E3-ubiquitin ligase PAM.

  2009cited by this paper
• S1P1 receptor overrides regulatory T cell-mediated immune suppression through Akt-mTOR

  2009cited by this paper
• FTY720 (fingolimod) in Multiple Sclerosis: therapeutic effects in the immune and the central nervous system

  2009cited by this paper
• FTY720 Reduces Inflammation and Promotes Functional Recovery after Spinal Cord Injury

  2009cited by this paper
• S1P(2) receptors mediate inhibition of glioma cell migration through Rho signaling pathways independent of PTEN.

  2008cited by this paper
• Central nervous system-directed effects of FTY720 (fingolimod).

  2008cited by this paper
• FTY720 therapy exerts differential effects on T cell subsets in multiple sclerosis

  2008cited by this paper
• Oral Fingolimod (FTY720) for Relapsing Multiple Sclerosis

  2008cited by this paper

• Nanoformulated fingolimod attenuates NLRP3 inflammasome activation and promotes functional recovery in a rat model of spinal cord injury.

  2026cites this paper
• Metabolomics-driven exploration of sphingosine 1-phosphate mechanisms in refractory epilepsy.

  2025cites this paper
• Dietary Interventions Targeting the Neurolipidome in Epilepsy: From Preclinical Models to Clinical Applications and Future Therapeutic Approaches.

  2025cites this paper
• Microglial phagocytosis in epilepsy: Mechanisms and impact

  2025cites this paper
• Immune System and Brain/Intestinal Barrier Functions in Psychiatric Diseases: Is Sphingosine-1-Phosphate at the Helm?

  2023cites this paper
• Seizures and multiple sclerosis‑more than an epidemiological association (Review)

  2022cites this paper
• An Insight on Molecular Mechanisms & Novel Therapeutic Approaches in Epileptogenesis.

  2020cites this paper
• From the Molecular Mechanism to Pre-clinical Results: Anti-epileptic Effects of Fingolimod

  2020cites this paper
• Tenidap suppresses epileptiform burst discharges in cultured hippocampal neurons by activation of Kir2.3 channels.

  2019cites this paper
• WAG/Rij rat model: a resource for the pharmacology of epileptogenesis and related neurological/psychiatric comorbidities

  2019cites this paper
• Epilepsy in multiple sclerosis as a network disease.

  2019cites this paper
• Synthesis and evaluatation of N-substituted (Z)-5-(benzo[d][1,3]dioxol-5-ylmethylene)-2-thioxothiazolidin-4-one derivatives and 5-substituted-thioxothiazolidindione derivatives as potent anticonvulsant agents.

  2019cites this paper
• Pharmacology of epileptogenesis and related comorbidities in the WAG/Rij rat model of genetic absence epilepsy.

  2018cites this paper